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Abstract We report for the ¢rst time the a⁄nity maturation of
Fab antibody fragments using £uorescent-activated cell sorting
(FACS) of yeast-displayed repertoires. A single yeast display
vector which enables the inducible expression of an anchored
heavy chain and a soluble light chain has been constructed.
The assembly and functional display on the yeast cell surface
of Fab antibodies speci¢c for di¡erent protein targets has been
demonstrated by £ow cytometry and immuno£uorescence mi-
croscopy. We have a⁄nity matured a Fab antibody speci¢c
for the tetravalent antigen streptavidin using FACS of yeast-
displayed repertoires diversi¢ed by error-prone polymerase
chain reaction. A panel of variants with up to 10.7-fold improve-
ment in a⁄nity was obtained after selection. Two leading
clones, R2H10 (3.2 nM) and R3B1 (5.5 nM), had mutations
in light chain complementarity determining region 1 LC-
CDR1 (H34R) and LC-CDR3 (Y96H or Y96F) and gave a
10.7-fold and 6.3-fold a⁄nity improvement over the starting
antibody, respectively. The ability to e⁄ciently a⁄nity mature
Fab antibodies is an important component of the antibody de-
velopment pipeline and we have shown that yeast display is an
e⁄cient method for this purpose.
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1. Introduction
The past decade has seen recombinant antibodies become
an increasingly important group of drugs, which currently
represent over 30% of biopharmaceuticals in clinical trials.
As such, their rapid isolation, characterisation and optimisa-
tion are of critical importance. The advent of phage display
has done much to accelerate antibody development [1] and
large ‘single pot’ phage-displayed human scFv [2] or Fab [3]
antibody libraries have been used for rapid isolation of bind-
ers to a broad range of disease-associated targets.
Although phage display is a very powerful technology for
the isolation of lead antibodies, these antibodies often require
a⁄nity optimisation prior to clinical development, as im-
proved binding generally correlates with improved clinical ef-
¢cacy. For example, it has been shown that increasing the
a⁄nity of antibodies improves selective tumour delivery,
which is likely to increase their utility in tumour imaging
and therapy [4]. It is, however, di⁄cult to predict what a⁄nity
threshold is required for any given therapeutic application
since this may not be the only determinant of biological po-
tency. Parameters such as antigen density, antigen location,
antibody speci¢city, antibody stability, antibody clearance
and immune e¡ector functions may also be important. How-
ever, these parameters are not as easily manipulated as anti-
body a⁄nity [5]. The antigen location and concentration may
be of particular signi¢cance. For example, the a⁄nity required
to bind and neutralise a soluble target may be much higher
than that which is required for speci¢c binding to a cell sur-
face-bound target. This is illustrated by the therapeutic a⁄n-
ities of two very di¡erent clinically approved antibodies, Re-
micade1 for the treatment of rheumatoid arthritis and
Herceptin1 for the treatment of breast cancer. Remicade1
is speci¢c for soluble tumour necrosis factor K and has an
apparent a⁄nity of 100 pM [6], whereas Herceptin1 binds
to the cell surface HER-2/neu proto-oncogene and has a sig-
ni¢cantly lower a⁄nity, of 5 nM [7]. Generally antibodies that
bind with low nM (1^10 nM) monovalent binding a⁄nities to
cell surface targets can be expected to be a minimum require-
ment for clinical development. For cell surface targets, the
a⁄nity of lead antibodies from phage display libraries some-
times falls within this range; however, for applications such as
cytokine neutralisation it can be expected that a⁄nity im-
provements of at least 10-fold will generally be required.
Thus there is a clear need for a⁄nity maturation methods
that can give reliable improvements in a⁄nity quickly.
A⁄nity maturation requires the generation of secondary
diversi¢ed libraries, from which isolates with improved a⁄nity
are then selected. Various methods of antibody gene diversi-
¢cation have been described, ranging from non-directed ap-
proaches (i.e. mutator strains, V-gene chain shu¥ing, error-
prone polymerase chain reaction (PCR) or DNA shu¥ing), to
approaches where mutations are targeted to the antibody’s
complementarity determining region (CDR) (i.e. parsimonious
mutagenesis, CDR randomisation or hot-spot mutagenesis
[8]). The ability to quantitatively select these secondary libra-
ries for improved variants is of critical importance and has
0014-5793 / 03 / $22.00 J 2003 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
doi:10.1016/S0014-5793(03)00602-1
*Corresponding author.
E-mail address: shufton@dyax.com (S.E. Hufton).
Abbreviations: CDR, complementarity determining region; VH, var-
iable region of an antibody heavy chain; VL, variable region of an
antibody light chain; FACS, £uorescent-activated cell sorting; LC,
light chain; HC, heavy chain
FEBS 27377 18-6-03
FEBS 27377FEBS Letters 546 (2003) 288^294
generally been accomplished using phage display [9,10] ; how-
ever, recent advances in yeast display technology have made
this process much more e⁄cient [11,12]. The successful appli-
cation of yeast display to antibody a⁄nity maturation can be
largely attributed to the fact that repertoires can be selected
by £ow cytometric cell sorting. This selection process with
untethered antigen allows for quantitative assessment of anti-
gen binding and display level of each individual antibody-
displaying yeast cell [13,14]. In contrast, selection for im-
proved a⁄nity can be less predictable using phage display,
particularly with immobilised target, and can lead to selection
for parameters other than improved a⁄nity [15^18].
Previous studies using yeast display have described the af-
¢nity maturation of single chain molecules such as scFv anti-
body fragments [11,19] and scTCR molecules [20]. However,
as yet this technology has not been used for the maturation of
heterodimeric molecules anchored by one member of a pair of
distinct polypeptides. We describe for the ¢rst time the display
and a⁄nity maturation of a heterodimeric Fab antibody spe-
ci¢c for the tetravalent protein target streptavidin, using £uo-
rescent-activated cell sorting (FACS) selection of yeast-dis-
played repertoires.
2. Materials and methods
2.1. Construction of yeast Fab display vector
The pYD1 yeast display vector (Invitrogen) was engineered for the
display of antibody Fab fragments into vector pTQ3 (Fig. 1A). This
modi¢ed vector allows the tandem expression of soluble light chains
(LC) and heavy chains (HC) fused to the Aga2p yeast cell surface
anchor protein. To make the vector compatible with our phage dis-
play and IgG expression systems, three ApaLI sites (1393, 3047, 4293)
were removed from pYD1 by Quikchange site-directed mutagenesis
(Stratagene) according to the manufacturer’s instructions. In the
AGA2 signal sequence a NheI cleavage site was introduced by site-
directed mutagenesis. A polylinker was constructed by annealing com-
plementary oligonucleotides and cloned as a NheI/PmeI fragment into
the modi¢ed pYD1 vector. This polylinker introduced unique cloning
sites (ApaLI, AscI, BamHI, PstI, EcoRI, PacI and PmeI) in the vector
and a haemagglutinin (HA) epitope tag at the 3P end of the AGA2
signal sequence. The ApaLI/AscI unique restriction sites were to facil-
itate cloning of LC fragments. The K1 mating factor transcriptional
terminator (MatK) was ampli¢ed by PCR from the original pYD1
vector and cloned behind the HA tag as a BamHI/PstI fragment. A
part of the expression cassette of pYD1 containing the GAL1 pro-
moter, AGA2 signal sequence, AGA2 gene and glycine/serine linker
was ampli¢ed by PCR using a reverse primer that incorporates the c-
myc epitope tag and the S¢I/NotI restriction sites for HC cloning.
This fragment was cloned behind the ¢rst MatK terminator sequence
as a EcoRI/PacI fragment to give the ¢nal vector construct pTQ3.
2.2. Flow cytometric analysis of yeast cells
Induction of antibody expression and £ow cytometric analysis was
performed as described previously [21]. Brie£y, yeast cells were grown
to logarithmic phase and induced with galactose 2% (w/v) for 48 h at
20‡C with shaking. After induction cells were labelled with anti-c-myc
(25 Wg/ml) or anti-HA (25 Wg/ml) (Roche) for 1 h at room temper-
ature. Subsequently cells were incubated on ice for 1 h with 1:40
rabbit anti-mouse £uorescein isothiocyanate (FITC) and 500 nM
streptavidin-PE. Cells were washed once with 0.5 ml phosphate-bu¡-
ered saline (PBS) between all labelling steps and were analysed on an
Epics Altra £ow cytometer (Beckman Coulter). For determination of
dissociation rate constants cells were resuspended in 1 WM unlabelled
streptavidin after the ¢nal wash and antigen binding was monitored
over a 30 min period. The decrease in £uorescence over time was ¢tted
to an exponential decay model from which o¡ rate was determined as
described [21].
2.3. Construction of diversi¢ed repertoires by error-prone PCR
The anti-streptavidin Fab fragment F2 was randomly mutated us-
ing error-prone PCR as described previously [22]. Brie£y, the Fab was
ampli¢ed from pTQ3 vector using primers 5P-ACG ACG TTC CAG
ACT ACG C-3P and 5P-TTC AGA TCC TCT TCT GAG ATG AG-
3P. After puri¢cation of the PCR products they were digested with
ApaLI and AscI for the LC, S¢I and NotI for the HC or ApaLI and
NotI for the cloning of the whole Fab fragment. The digested prod-
ucts were gel puri¢ed by Wizard PCR and cloned separately into
similarly treated empty pTQ3 vector or vector containing either
wild-type LC or wild-type HC. For the construction of the Fab rep-
ertoire the phage expression cassette was replaced by the yeast expres-
sion cassette from pTQ3 as an AscI/S¢I fragment. Plasmid DNA was
prepared from these libraries using a Qiagen plasmid puri¢cation kit
and was subsequently transformed into the yeast strain EBY100 as
described previously [23].
2.4. Library selection
The mutant F2 repertoires were grown overnight and antibody
expression was induced for 48 h as described above. The repertoire
was labelled with anti-HA (25 Wg/ml) for 1 h at room temperature
followed by a secondary incubation with rabbit anti-mouse Ig-FITC
(1:40) and 6 nM streptavidin-PE (Dako). Cells were washed once with
0.5 ml PBS following all incubation steps, after the ¢nal wash cells
were kept on ice to prevent antigen dissociation. Samples were sorted
on a Epics Altra £ow cytometer with a sorting rate of approximately
2000 cells/s.
2.5. Protein analysis
Monoclonal yeast cultures were grown and induced as described
above. After induction yeast cells were microfuged for 10 min at
13 000 rpm, washed with 1 ml milli-Q water and resuspended in 250
Wl sodium dodecyl sulphate (SDS) sample bu¡er (10 mM Tris^HCl
pH 6.8, 2% SDS, 15% glycerol). Glass beads (Sigma) were added to
just below the meniscus and cells were vortexed four times for 1 min
on ice. Finally, cell debris was removed by centrifugation at 13 000
rpm and samples were boiled for 10 min.
Protein samples were analysed by SDS^polyacrylamide gel electro-
phoresis through 12.5% Tris/glycine gels as described [3].
2.6. Surface plasmon resonance analysis
Kinetic measurements were preformed on a Biacore 30001 (Bia-
core, AB). Approximately 500 RU streptavidin was immobilised on a
CM5 sensor chip by standard amine coupling. Association and dis-
sociation rate constants were determined by injection of a concentra-
tion range of each soluble Fab protein at a constant £ow rate of 30 Wl/
min to avoid rebinding e¡ects. All injections were performed in du-
plicate. Sensorgrams were analysed using BIAevaluation software
3.11.
3. Results
3.1. Construction and evaluation of a yeast Fab display vector
A single yeast display vector was constructed comprising
two expression cassettes driven by identical inducible GAL1
promoters (Fig. 1A). We reasoned that this format would lead
to the production of stoichiometric amounts of separate LC
and HC polypeptides and thus optimise the yield of functional
Fab antibodies. The HC was fused at its N-terminus to the
Aga2p yeast cell surface anchor protein, whereas the LC was
produced as a soluble fragment. This format is also the most
frequently used for Fab display on phage by the p3 coat
protein [3]. The AGA2 signal sequence was appended to
both LC and HC to drive processing of each polypeptide
through the yeast secretion apparatus, ultimately leading to
an assembled heterodimeric protein on the yeast cell surface.
The addition of di¡erent epitope tags to the N-terminus of the
LC and the C-terminus of the HC allows simultaneous and
independent monitoring of display of each polypeptide chain
and permits normalised selection [11].
This new display system was validated using three Fab anti-
bodies isolated from a large Fab repertoire [3], speci¢c for
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streptavidin (clone pTQ3-F2), the breast epithelial cancer
marker mucin-1 (clone pTQ3-PH1) [24] and cytotoxic T-lym-
phocyte-associated antigen-4 (data not shown). Whole cell
extracts were made of normal and induced yeast cells contain-
ing the pTQ3-F2 or pTQ3-PH1 antibody expression con-
structs. Western blotting showed a HC product of the ex-
pected molecular weight of 33 kDa (Fig. 1B). The doublet
band probably corresponds to Aga2p-HC protein with and
without a signal sequence. LC product was also detected at
the expected molecular weight of approximately 25 kDa.
To evaluate if yeast cells can functionally assemble hetero-
dimeric Fab antibodies on their surface we induced antibody
expression followed by testing for Fab display and antigen
binding in yeast whole cell enzyme-linked immunosorbent as-
say (data not shown), £ow cytometry (Fig. 1C) and immuno-
£uorescence microscopy (Fig. 1D). Yeast cells were labelled
for the detection of HC, LC and antigen binding. In all cases
LC and HC could be detected on the yeast cell surface and the
Fab was functionally accessible for binding to antigen. Anti-
gen binding was speci¢c with no cross-reactivity with non-
relevant antigens (data not shown). Speci¢city could be fur-
ther con¢rmed by competition with unlabelled antigen (Fig.
1C). Simultaneous labelling of HC and LC using two-colour
immuno£uorescent microscopy demonstrated the pairing of
both chains on the surface of individual yeast cells. Analysis
of a monoclonal culture expressing target-speci¢c Fab anti-
body fragments showed that approximately 60% of the total
cell population displayed functional Fab with antigen binding
activity (Fig. 1C), this is consistent with previous studies using
scFv fragments [21].
Fig. 1. Functional evaluation of Fab display on yeast cells. A: Two identical GAL1 promoters allow the expression of LC- and HC-Aga2p fu-
sion. Display of LC and HC can be independently monitored using the appended epitope tags HA (LC) and c-myc (HC). Aga2p refers to the
Aga2p subunit of the a-agglutinin yeast cell surface anchor protein; SS refers to the Aga2p signal sequence. B: Expression of Fab antibody
fragments F2 and PH1 in Saccharomyces cerevisiae before (3) and after (+) 48 h induction, detection of (a) HC-Aga2p fusion product and (b)
LC fragments. C: Yeast cells transformed with pTQ3-F2 (left panels) and pTQ3-PH1 (right panels) were left untreated (dotted line) or induced
for 48 h at 20‡C (light grey line). HC display (a), LC display (b) and antigen binding (c) were analysed using £ow cytometry. Speci¢c binding
was demonstrated by competition with unlabelled antigen (dark grey). D: Two-colour immuno£uorescent detection of assembled Fab antibod-
ies on the yeast cell surface; (a) phase contrast, (b) detection of HC, (c) detection of LC.
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3.2. Model enrichment experiments using FACS
We performed single pass enrichment experiments using a
mixture of yeast cells displaying an anti-streptavidin Fab
(pTQ3-F2) antibody and control cells not displaying an anti-
body. Positive and negative yeast cells carried expression plas-
mids with di¡erent selectable markers for tryptophan and
leucine respectively. This allowed simple calculation of enrich-
ment factors by titration on selective plates before and after
selection. Enrichment factors of up to 212-fold were obtained
using FACS depending on the initial purity of the speci¢c Fab
fragment. Enrichment factors of the same order of magnitude
have been reported using model selection experiments with
antibodies in the scFv format [11].
Similar experiments were performed to determine if we
could preferentially enrich a high a⁄nity clone from an excess
of lower a⁄nity clones with the same speci¢city. Mixtures of
pTQ3-F2 (34 nM) and pTQ3-A12 (500 nM) carrying di¡erent
auxotrophic markers were labelled at ¢ve antigen concentra-
tions spanning the a⁄nities of the two antibodies (Table 1).
The cell mixture was simultaneously labelled for antigen bind-
ing and Fab display, and cells were sorted for both parame-
ters in high purity mode with a sort window of approximately
1%. Enrichment factors were determined by titration on selec-
tive plates and the optimum enrichment factor of 38-fold was
found at an antigen concentration of 50 nM. This empirical
value showed good agreement with the theoretical optimum
labelling concentration of 62 nM determined using the math-
ematical model of Boder and Wittrup [13].
3.3. A⁄nity maturation of streptavidin-speci¢c Fab fragment
We chose to a⁄nity-mature a streptavidin-speci¢c Fab anti-
body fragment F2. Antibody V genes were diversi¢ed using
error-prone PCR [22] introducing mutations into the LC only,
HC only or into the whole Fab gene, resulting in three rep-
ertoires with 5U106, 1.7U106 and 1U106 individual yeast
clones respectively. The mutation frequency at the amino
acid level was determined as 3% for the LC and 1.3% for
the HC.
Three rounds of equilibrium selections were performed us-
ing FACS. An optimum antigen concentration of 6 nM was
calculated, using a mathematical model [13], to be required
for a predicted ¢ve-fold improvement in a⁄nity. A reaction
volume was chosen to maintain a 10-fold molar excess of
labelled ligand over displayed Fab assuming approximately
105 copies of Fab per yeast cell. This was important to min-
imise selection on the basis of avidity since the selections were
performed with the multimeric antigen streptavidin. During
each selection round the stringency was increased by gating
a smaller percentage of the highest antigen binding population
(sequentially gate 5%, 1% and 0.5%). The selection campaign
was monitored by performing £ow cytometric analysis of the
polyclonal outputs of each selection round (Fig. 2). It can be
seen that the number of cells in the gated population increased
during selection, indicating that selection was proceeding to-
wards higher a⁄nity antibodies.
Sequence analysis of the selected clones from the selection
campaigns of all three repertoires had gone to completion
with a limited number of clones dominating the third round
of selection (Table 2). The sequence of selected variants had
reduced to two di¡erent clones from the LC repertoire (H34R/
Y96H and S2P/D85V), two di¡erent clones from the HC rep-
ertoire (H53R and H53R/S62A) and six di¡erent clones from
the Fab repertoire. These selected clones were initially
screened for a possible improvement in o¡ rate using £ow
cytometric analysis of Fabs displayed on yeast cells [11].
The decrease in £uorescence over time was ¢tted to an expo-
nential decay model from which the dissociation rate con-
stants were calculated. These range from 3.5U1034 s31 to
0.5U1034 s31 compared to 2.2U1034 s31 for the starting
Table 1
A⁄nity discrimination of two yeast-displayed Fab antibodies of di¡erent a⁄nities
Antigen (nM)a Titre (3Trp)b Titre (3Trp/3Leu)
Fab-A12c
Titre (3Trp)3(3Trp/3Leu)
Fab-F2d
Percentage
Fab-F2e
Enrichmentf
Input 3.7U107 3.7U107 4.7U105 1.3
Output
500 9U103 8.9U103 100 1.1 0.9
100 1.3U103 7.9U102 5.6U102 43 33
50 2.4U103 1.2U103 1.2U103 50 38
25 1.2U103 9.1U102 3.2U102 26 20
10 1.53U103 1.49U103 45 3 2.3
aAntigen concentration used for labelling yeast cells prior to FACS.
bTitre on 3Trp selective plates.
cTitre on 3Trp/3Leu selective plates representative of the number of yeast colonies containing antibody construct pTQ3-A12.
dTitre on 3Trp plates minus titre on 3Trp/3Leu selective plates representative of the number of yeast colonies containing antibody construct
pTQ3-F2.
eThe percentage of yeast cells containing the higher a⁄nity antibody pTQ3-F2.
fThe ratio of positive to negative yeast cells before and after selection.
Fig. 2. Polyclonal £ow cytometric analysis. Dotplots of antigen
binding and Fab display are shown for the unselected library (a)
and polyclonal outputs of selection rounds 1, 2 and 3 (b^d) The
sorting gate used in each library selection is indicated.
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wild-type antibody which corresponds to up to a 4.4-fold
improvement in o¡ rate (Table 2).
A more accurate a⁄nity screening was performed with solu-
ble Fab fragments. For this the majority of the selected var-
iants were re-cloned into an Escherichia coli expression vector
[3]. A⁄nity analysis of puri¢ed soluble Fab fragments ob-
tained using Biacore1 and immobilised streptavidin showed
that the dissociation rate constants were signi¢cantly faster
than the dissociation rate constants obtained with £ow cytom-
etry. Although the absolute dissociation rate values were dif-
ferent for the two techniques the relative ranking of clones
remains the same. The overall improvement in a⁄nity varied
from 1.6- to 10.7-fold compared to the wild-type F2, with
clone R2H10 (Fig. 3) and R3B1 giving the greatest improve-
ments in a⁄nity to 3.2 nM and 5.5 nM respectively (Table 2).
We also investigated if consensus mutations in the LC could
be combined with those identi¢ed in the HC to have a syner-
gistic e¡ect. The best LC mutants (R2H10 and R3B1) were
combined with a dominant HC (R3G4), resulting in two new
clones called Hyb1 and Hyb2 (Table 2). A⁄nity screening of
the soluble Fab fragments revealed two-fold improved on
rates for both clones; however, this was accompanied by a
faster o¡ rate. Although there was modulation of the o¡ and
on rates no additive e¡ect could be seen.
4. Discussion
Lead antibodies from primary selections of naive phage
antibody libraries generally contain antibodies in either the
scFv or Fab format. Although both formats are widely ac-
cepted there may be advantages in adopting the Fab antibody
format for antibody development. The ¢rst potential advan-
tage lies in reformatting to whole IgG, which is generally
required prior to clinical development [25^28]. Although
both scFv and Fab antibodies have been successfully refor-
matted into whole IgG, the conversion of Fab fragments may
be more predictable due to the more natural format in com-
parison to the arti¢cially restrained scFv format. Secondly
there is a stronger association between the two chains of a
Fab fragment compared to the pairing of the variable regions
of antibody heavy and light chains (VH and VL) in a scFv
fragment. As this stable pairing is essential for e¡ective anti-
gen binding there is more scope for simple improvement in the
associations of VL and VH domains at the expense of real
a⁄nity improvements via optimisation of the antigen binding
site. One report on the maturation of scFv by yeast display
reported that four out of 10 selected mutations were located
at the VH^VL interface suggesting that improved stability
and/or orientation of the VH^VL domain pairing may repre-
sent important initial changes required prior to changes at the
antigen binding site [19]. Such mutations may not be of any
relevance for the a⁄nity of an antibody after conversion to
whole IgG and may simply be related to an optimisation of
the scFv format. When using Fabs such artefacts may well be
avoided. Furthermore, the tendency of scFv antibodies to
dimerise through possible acquired mutations in the V gene
or £exible linker can complicate a⁄nity selection using phage
display [15,17] and may be expected to be the same for yeast
display.
We have shown that Fab antibodies can be displayed on the
Table 2
Characterisation of a⁄nity-improved Fab fragments
Clone Library Mutation FACSc Biacorec
Variable LCa;b Variable HCa;b kd (1034 s31) kd (1033 s31) ka (104 M31s) KD (nM) Improvement
wt F2 ^ wt wt 2.2 V 1.0 1.52V0.15 4.51V 0.01 34 ^
R2H10 LC H34R, Y96H none 0.5 V 0.1 0.18V0.01 5.69V 0.02 3.2 10.7
R3A9 LC S2P, D85V none 1.3 V 0.1 1.53V0.57 7.84V 0.08 19.5 1.7
R3H4 HC none H53R 1.9 V 0.7 N.D. N.D. N.D. N.D.
R3D2 HC none H53R, S62A 1.6V 0.6 N.D. N.D. N.D. N.D.
R2D3 Fab H34R 1 silent mut. 2.1 V 0.3 1.04V0.10 5.76V 0.08 18.1 1.9
R3H1 Fab Y96F A23V, S65R 1.0 V 0.4 0.28V0.04 3.25V 1.14 8.7 3.9
R3G4 Fab S2P, D85V H53R, A84T 3.5V 1.1 2.37V0.25 10.9V 1.13 21.7 1.6
R3B1 Fab Y96F P40L 0.9V 0.2 0.22V0.05 4.00V 1.30 5.5 6.3
R3E1 Fab S2P, D85V K14E 2.1V 1.2 1.03V0.10 7.64V 0.95 13.5 2.5
R3H3 Fab Q79R Q3R 2.0V 1.0 1.04V0.04 11.3V 2.64 9.2 3.7
Hyb1 Constructed
hybrid
H34R, Y96H H53R, A84T N.D. 0.49V0.03 13.7V 0.13 3.6 9.4
Hyb2 Constructed
hybrid
Y96F H53R, A84T N.D. 0.34V0.24 7.71V 0.04 4.4 7.6
wt: wild-type; N.D.: not determined.
aAntibody residue numbering according to Kabat et al. [32].
bMutations in bold are in the CDR loops.
cReported values are the means with standard deviation of three independent experiments.
Fig. 3. A⁄nity determination using Biacore1. Association and dis-
sociation rate constant analysis of clone R2H10. Continuous lines,
injection of puri¢ed R2H10 Fab at (from top to bottom) 462 nM,
232 nM, 116 nM and 58 nM. Broken line, injection of puri¢ed
wild-type F2 Fab at 500 nM.
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yeast cell surface and that these antibodies are functionally
accessible to large protein antigens. Our yeast display vector
was designed so that the polarity of the two chains was com-
patible with our phage display Fab libraries for initial lead
identi¢cation [3] (Ladner et al., manuscript in preparation)
and also with vectors used for whole IgG reformatting and
production. This compatibility in format and design allows
for the ‘batch transfer’ or the ‘combinatorial transfer’ of se-
lected Fab fragments between phage, yeast and mammalian
expression systems. The ‘batch transfer’ of selected pools of
Fab fragments is distinguished from ‘combinatorial transfer’
in that it retains selected LC and HC combinations. This may
be the preferred cloning strategy when the pool of Fabs is so
large that the separate transfer of LC and HC risks losing
optimum antigen-positive LC/HC combinations. The ‘combi-
natorial transfer’ on the other hand can be used for chain
shu¥ing procedures in order to create new LC and HC com-
binations.
Our study demonstrates that quantitative selection of yeast-
displayed repertoires using FACS is an e⁄cient method for
a⁄nity maturation of Fab antibody fragments. The a⁄nity of
a model antibody speci¢c for the challenging multivalent tar-
get streptavidin was improved 10.7 fold to 3.2 nM, applying
one cycle of mutagenesis in combination with FACS selection.
We noted that all selected variants have improved a⁄nity and
showed an average of one to two mutations (at the amino acid
level) per variable region. Clones with the highest improve-
ment in a⁄nity had mutations LC-H34R (CDR1) and LC-
Y96H (CDR3) or LC-Y96F (CDR3). In all cases the muta-
tions are conservative substitutions, either substituting like
positive charges as in LC-H34R (CDR1) or exchanging aro-
matic groups like LC-Y96H or LC-Y96F (CDR3). Other
clones with smaller a⁄nity improvements due to improved
association rate carried mutations LC-S2P (FR1) and LC-
D85V (FR3) alone or in combination with HC-H53R
(CDR2). The mutation of Y96 to two di¡erent amino acids
suggests the importance of this residue in antigen binding and
furthermore the substitution of other aromatic amino acids
suggests particular structural requirements at this site. Each
of these substitutions requires a single base change. The o¡
rate of selected clones was determined both as yeast-displayed
Fab by FACS and as soluble Fab by BIAcore1. The ranking
of the clones was consistent between the two assays with the
three clones R2H10, R3B1 and R3H1 being ranked in iden-
tical order of increasing o¡ rate in both assays. However, we
did note a consistent di¡erence between the absolute o¡ rate
values of the two assays in that the FACS-based assay gave a
slower o¡ rate for wild-type F2 and the variants obtained
after selection. This di¡erence was most likely due to avid
binding of the multivalent streptavidin molecule to multiva-
lent Fab displayed on the yeast cell surface. As this relative
di¡erence between the two assays was consistent between
clones we conclude that the normalised FACS selection was
successful and we did not select clones on the basis of higher
display. Since many clinically relevant target antigens are pro-
duced as multivalent molecules (e.g. Fc fusions) it is critical
that any a⁄nity maturation strategy is not compromised by
the use of multivalent targets. We have shown that this is not
a signi¢cant concern using yeast display and that by using
normalised FACS selection of relatively small Fab repertoires
speci¢c for a tetravalent antigen we have recovered a panel of
antibodies all with improved monovalent binding a⁄nity.
The combination of the dominant CDR mutations LC-
H34R (CDR1), LC-Y96H/F (CDR3) and HC-H53R (CDR2)
was not retrieved from the Fab library. A possible explanation
for this is that the clone was not present in the library since
the sequence space sampled in this repertoire is smaller than
that of the separate HC and LC libraries. Another explana-
tion is that the mutations in LC and HC were not synergistic,
resulting in a lower intrinsic a⁄nity or stability. To test this,
variants were constructed from the dominant LC and HC.
The variants Hyb1 and Hyb2 gave improved a⁄nity relative
to wild-type; however, there appeared to be no synergistic
e¡ect. As such it seems that the former is the likely explana-
tion for the absence of the combinatorial clones Hyb1 and
Hyb2 from the starting Fab repertoire.
The mutation rate in our starting libraries was relatively
high (1.4% for LC and 0.7% for HC at the nucleotide level)
and the percentage of antigen binding clones was between 2
and 10% depending on the library. This percentage of active
clones was in agreement with Georgiou and coworkers [22]
who reported that a library with a mutation frequency of
0.5% nucleotide mutations gave 6.7% active clones. Although
our libraries only sparsely sample a very large theoretical se-
quence space, we were able to select mutants with a signi¢-
cantly higher a⁄nity after only one cycle of mutagenesis and
selection. Greater a⁄nity improvements can be obtained by
iterating the process of mutagenesis and selection. This has
been most e¡ectively demonstrated by Wittrup and colleagues
who using four cycles of DNA shu¥ing and selection of yeast-
displayed scFv repertoires were able to get over a 1000-fold
improvement in a⁄nity to 48 fM for an anti-£uorescein scFv
[19]. Our data suggest that this will also be possible for Fab
antibodies.
The rapid and e⁄cient generation of high a⁄nity antibodies
is an important step in the development of antibodies for
immunotherapy of many disease indications including cancer
[4,29] and microbial pathogenicity [30,31]. The a⁄nity matu-
ration process should be integrated not only with technologies
for initial lead identi¢cation (such as from phage display rep-
ertoires) but also with technologies to build pharmaceutical
leads (such as reformatting to whole IgG). Our yeast display
system is fully compatible with both components of the anti-
body development pipeline. We have shown that antibodies in
the Fab format can be a⁄nity-matured without di⁄culty us-
ing quantitative FACS a⁄nity selection of relatively small
libraries of 106^107 yeast-displayed variants. Furthermore,
our proof that Fab antibodies compromising two distinct
polypeptides can be displayed on yeast cells invokes library
construction strategies based on combinatorial yeast mating
of separate LC and HC repertoires (Hufton, Blaise et al.,
manuscript in preparation). Such combinatorial yeast mating
technology will ¢nd applications in both antibody a⁄nity
maturation and in the generation of large non-immune reper-
toires for initial lead identi¢cation.
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